Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AdOral Sema
- Development stage
- Preclinical
- Lead developer
- Adocia
- Modality
- Peptides
- Administration
- Oral, Subcutaneous
01
Overview
AdOral Sema is an orally administered formulation of semaglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist. Developed by Adocia, this product leverages the proprietary AdOral technology to enhance the oral bioavailability of semaglutide, which is typically administered via injection. Preclinical studies indicate that the absorption and bioavailability of semaglutide are significantly improved with this formulation compared to existing oral options such as Rybelsus. Semaglutide itself is approved for type 2 diabetes management, weight loss, and weight maintenance due to its ability to reduce appetite, delay gastric emptying, increase insulin release in response to meals, and lower glucagon secretion[10][3][4].
- Brand names
- AdOral Sema
- Other names
- AdOral Sema
02
Targets
Beyond the preview
Go deeper on AdOral Sema.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AdOral Sema.